• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pieris Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
November 20, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 07, 2024
From Palvella Therapeutics
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
From Palvella Therapeutics
Via GlobeNewswire
News headline image
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 10, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
March 29, 2023
Via ACCESSWIRE
News headline image
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
September 03, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders
August 17, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
August 16, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
July 24, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 02, 2022
Via ACCESSWIRE
News headline image
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
July 24, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 24, 2024
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
April 19, 2024
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
March 27, 2024
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
August 17, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
July 18, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
June 21, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 02, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 22, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 21, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 04, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
May 02, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
April 17, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
March 24, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
January 10, 2023
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
November 23, 2022
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 09, 2022
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
November 01, 2022
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
October 26, 2022
Via ACCESSWIRE
News headline image
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap